SCOTT ARTHUR WALDMAN, MD, PhD, FCP, FAHA, FNAI, FASPET CURRICULUM VITAE

CURRENT POSITIONS (Thomas Jefferson University)

Chair, Department of Pharmacology, Physiology and Cancer Biology Samuel MV Hamilton Professor of Medicine Director, MD-PhD Program Sidney Kimmel Medical College

ADDRESS

Department of Pharmacology, Physiology and Cancer Biology Thomas Jefferson University 132 South 10th Street 1170 Main Philadelphia, Pennsylvania 19107

PERSONAL

Date of Birth:	October 22, 1953
Place of Birth:	Brooklyn, New York
Marital Status:	Married 1975, 2 Children

EDUCATION

Stanford University, Palo Alto, California School of Medicine: 1983-1987 M.D. conferred June, 1987

Thomas Jefferson University, Philadelphia, Pennsylvania Department of Anatomy, School of Medicine: 1975-1979 Ph.D. conferred June, 1980 Majors: Human Anatomy, Biochemistry Minor: Developmental Biology

State University of New York at Albany, Albany, New York: 1971-1975 B.S. conferred May, 1975 Major: Biology

Minor: Chemistry

FELLOWSHIPS

DOCKE⁻

1979-1983	Postdoctoral Fellow, Division of Clinical Pharmacology, Department of Medicine, Advisor, F. Murad, M.D., Ph.D. (<i>1998 Noble Laureate in Physiology or Medicine</i>)	
	1981-1983 1979-1981	Stanford University, Palo Alto, California. University of Virginia, Charlottesville, Virginia.
1975-1979	Department of Anatomy, Thomas Jefferson University, Philadelphia, Pennsylvania; Advisor, K Chepenik, Ph.D.	
	1976-1979	NIH Predoctoral Fellow.
	1975-1976	Foederer Predoctoral Fellow

CLINICAL TRAINING

- 1988-1990Resident, Department of Medicine, Stanford University Hospital, Palo
Alto, California.
- 1987-1988 Intern, Department of Medicine, Stanford University Hospital, Palo Alto, California.

CERTIFICATION AND LICENSURE

1994	Diplomate of the American Board of Clinical Pharmacology.
1991	Physicians and Surgeons Certificate, Licensure by the State of Pennsylvania,
	Medical License.
1990	Diplomate, American Board of Internal Medicine, September 12, 1990
	(recertified 2000).
1988-1990	Physicians and Surgeons Certificate, Licensure by the State of California.
1988	Diplomate, National Board of Medical Examiners.

FACULTY APPOINTMENTS

Xuzhou Cancer Hospital, Xuzhou, China

05/21/2017-05/21/2020-Visiting Professor

University of Delaware, School of Health Sciences

06/01/2012-present- Adjunct Professor

Thomas Jefferson University, Philadelphia, Pennsylvania

2022-present Chair, Department of Pharmacology, Physiology and Cancer Biology.

- 2011-2015 Director, Jefferson Center for Individualized Medicine.
- 2010-2016 Vice President, Clinical and Translational Research, Thomas Jefferson University.
- 2010-2016 Associate Dean, Clinical and Translational Sciences, Jefferson Medical College.
- 2005-2022 Chair, Department of Pharmacology and Experimental Therapeutics. 1999-present Tenure granted.

1998-present Samuel M.V. Hamilton Professor of Medicine.

- 1997-present Director, Division of Clinical Pharmacology, Department of Medicine.
- 1996-1997 Associate Director of Clinical Trials, Office of Scientific Affairs.
- 1993-1998 Associate Professor of Medicine, Division of Clinical Pharmacology.

1993-1998 Associate Professor of Biochemistry and Molecular Pharmacology.

- 1991-present Graduate Faculty.
- 1990-1993 Assistant Professor of Medicine, Division of Clinical Pharmacology.
- 1990-1993 Assistant Professor of Pharmacology.

Veterans Administration Medical Center, Palo Alto, California

1983-1990 Staff Pharmacologist.

CLINICAL APPOINTMENTS

DOCKE.

RM

- 1991-present Attending Physician, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.
- 1991-1997 Medical Director, Clinical Research Unit, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

TEACHING ACTIVITIES

DOCKE.

Thomas Jefferson University

- 2007-present Lecturer, Advanced cellular and Molecular Immunology (IM605), Department of Microbiology and Immunology, (2 lecture hours).
- 2004-present Lecturer, Molecular Pharmacology (PR680), Department of Biochemistry and Structural Biology, (1.5 lecture hours).
- 2002-present Lecturer, Immunity, Infection and Disease (preclinical microbiology and immunology), Department of Microbiology and Immunology, (2 lecture hours).
- 2001-present Lecturer, Protein Structure and Function, Department of Biochemistry and Molecular Pharmacology (3 lecture hours).
- 2001-2005 Co-Director, Medical Pharmacology (PR 200) section of Foundations in Clinical Medicine (coordinate 36 lecture hours).
- 2000-present Director, Masters Programs in Pharmacology: Human Investigation Track, Department of Biochemistry and Molecular Pharmacology.
- 2000-present Program Director, NIH K30 Curriculum in Human Investigation.
- 1997-present Program Director, NIH Training Program in Translational Research for Summer Medical Students.
- 1997-present Director, MD-PhD Program.
- 1997-2000 Co-Director, Case Studies in Clinical Pharmacology (PR 760), Department of Biochemistry and Molecular Pharmacology (coordinate 24 lecture hours).
- 1997 Director, Clinical Pharmacology and Therapeutics (PR 401 (coordinate 60 lecture hours).
- 1996-present Program Director, NIH Postdoctoral Training Program in Clinical Pharmacology.
- 1996-present Director, Masters Programs in Pharmacology: Clinical Pharmacology Track, Department of Biochemistry and Molecular Pharmacology.
- 1995-1997 Director, Principles of Clinical Pharmacology (PR 525), Department of Biochemistry and Molecular Pharmacology (coordinate 45 lecture hours).
- 1994-present Lecturer, Principles of Clinical Pharmacology (PR 525), Department of Biochemistry and Molecular Pharmacology (6 lecture hours).
- 1994-present Director, Masters Program in Pharmacology: Clinical Scientist Track, Department of Biochemistry and Molecular Pharmacology.
- 1994-1997 Director, General Pharmacology (PR 522), Department of Biochemistry and Molecular Pharmacology (45 lecture hours).
- 1994-present Lecturer, General Pharmacology (PR 522), Department of Biochemistry and Molecular Pharmacology (3 lecture hours).
- 1993-present Lecturer, Molecular Pharmacology (PR670), Department of Biochemistry and Molecular Pharmacology (3 lecture hours).
- 1991, 1992 Medicine Grand Rounds, VA Hospital, Wilmington, Delaware (1 lecture hours).
- 1991, 1992 Medicine House Staff Lecture Series (1 lecture hour).
- 1991-1994 Instructor, Introduction To Clinical Medicine And Physical Diagnosis, Department of Medicine (6 contact hours).
- 1991-2000 Lecturer, Clinical Pharmacology and Therapeutics (PR 401), Department of Biochemistry and Molecular Pharmacology (4 lecture hours).

 1987 Invited Lecturer, graduate course in renal physiology, Department of Physiology. 1978 Student Instructor, course in transmembrane signaling and information cascades (Professor K.P. Chepenik), Department of Anatomy. 1977 Student Instructor, Neuroanatomy, (Professor Norman Moskowitz), Daniel Baugh Institute of Anatomy. 1977 Prosector and Student Instructor, Gross Anatomy (Professor Jay Shea), Daniel Baugh Institute of Anatomy. 1976 Student Instructor, Histology (Professor August Epple), Daniel Baugh Institute of Anatomy. 1976 Student Instructor, Histology (Professor August Epple), Daniel Baugh Institute of Anatomy. Stanford University 1990 Instructor, Introduction To Clinical Medicine And Physical Diagnosis (Christopher Snow, M.D.), Department of Medicine. 1990 Lecturer, Endocrine Physiology (Professor Andrew Hoffman), Department of Physiology. PRESENTATIONS 09/22 Clinical trials of GUCY2C (GCC) agonists for colorectal cancer prevention. Translational Advances in Cancer Prevention Agent Development (TACPAD). NCI. September 7-9, 2022. 10/19 Translating GUCY2C as a target for colorectal cancer. What every doctor should know: A general medical update. Vail, CO, February 3-6, 2019. 02/19 Paracrine hormone hypothesis of colorectal cancer. What every doctor should know: Ageneral medical update. Vail, CO, February 3-6, 2019. 09/18 Paracrine hormone hypothesis of colorectal cancer. Ionwood Pharmaceuticals, Inc., Cambridge, MA, July 14, 2018. 05/18 Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018. 03/18 Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018.	1991-present	Lecturer, Medical Pharmacology (PR 200), Department of Pharmacology (3 lecture hours).
 1978 Student Instructor, course in transmembrane signaling and information cascades (Professor K.P. Chepenik), Department of Anatomy. 1977 Student Instructor, Neuroanatomy, (Professor Norman Moskowitz), Daniel Baugh Institute of Anatomy. 1977 Prosector and Student Instructor, Gross Anatomy (Professor Jay Shea), Daniel Baugh Institute of Anatomy. 1976 Student Instructor, Histology (Professor August Epple), Daniel Baugh Institute of Anatomy. Stanford University 1990 Instructor, Introduction To Clinical Medicine And Physical Diagnosis (Christopher Snow, M.D.), Department of Medicine. 1990 Lecturer, Endocrine Physiology (Professor Andrew Hoffman), Department of Physiology. PRESENTATIONS 09/22 Clinical trials of GUCY2C (GCC) agonists for colorectal cancer prevention. Translational Advances in Cancer Prevention Agent Development (TACPAD). NCI. September 7-9, 2022. 10/19 Translating GUCY2C as a target for colorectal cancer. What every doctor should know: A general medical update. Vail, CO, February 3-6, 2019. 02/19 Paracrine hormone hypothesis of colorectal cancer. What every doctor should know: A general medical update. Vail, CO, February 3-6, 2019. 09/18 Paracrine hormone hypothesis of colorectal cancer. Ironwood Pharmaceuticals, Inc., Cambridge, MA, July 14, 2018. 05/18 Paracrine hormone hypothesis of colorectal cancer. Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018. 03/18 Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018. 2/18 Differentiating Therapies For ClC and IBS-C. Synergy Advisory Meeting, 	1987	
 1977 Student Instructor, Neuroanatomy, (Professor Norman Moskowitz), Daniel Baugh Institute of Anatomy. 1977 Prosector and Student Instructor, Gross Anatomy (Professor Jay Shea), Daniel Baugh Institute of Anatomy. 1976 Student Instructor, Histology (Professor August Epple), Daniel Baugh Institute of Anatomy. Stanford University 1990 Instructor, Introduction To Clinical Medicine And Physical Diagnosis (Christopher Snow, M.D.), Department of Medicine. 1990 Lecturer, Endocrine Physiology (Professor Andrew Hoffman), Department of Physiology. PRESENTATIONS 09/22 Clinical trials of GUCY2C (GCC) agonists for colorectal cancer prevention. Translational Advances in Cancer Prevention Agent Development (TACPAD). NCI. September 7-9, 2022. 10/19 Translating GUCY2C as target for colorectal cancer chemoprevention. Bench to Bedside and Beyond: Translational Research to Real World Evidence. Janssen, Titusville, NJ, October 8, 2019. 02/19 Paracrine hormone hypothesis of colorectal cancer. Unit International Conference on the Biology, Chemistry and Therapeutic Applications of Nitric Oxide, Oxford, UK, September 16-20, 2018. 07/18 Paracrine hormone hypothesis of colorectal cancer. Ironwood Pharmaceuticals, Inc., Cambridge, MA, July 14, 2018. 05/18 Paracrine hormone hypothesis of colorectal cancer. Inonwood Pharmaceuticals, Inc., Cambridge, MA, July 14, 2018. 05/18 Paracrine hormone hypothesis of colorectal cancer. Ivision of Clinical Pharmacology, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018. 03/18 Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018. 2/18 Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting, 	1978	Student Instructor, course in transmembrane signaling and information
 1977 Prosector and Student Instructor, Gross Anatomy (Professor Jay Shea), Daniel Baugh Institute of Anatomy. 1976 Student Instructor, Histology (Professor August Epple), Daniel Baugh Institute of Anatomy. Stanford University 1990 Instructor, Introduction To Clinical Medicine And Physical Diagnosis (Christopher Snow, M.D.), Department of Medicine. 1990 Lecturer, Endocrine Physiology (Professor Andrew Hoffman), Department of Physiology. PRESENTATIONS 09/22 Clinical trials of GUCY2C (GCC) agonists for colorectal cancer prevention. Translational Advances in Cancer Prevention Agent Development (TACPAD). NCI. September 7-9, 2022. 10/19 Translating GUCY2C as a target for colorectal cancer chemoprevention. Bench to Bedside and Beyond: Translational Research to Real World Evidence. Janssen, Titusville, NJ, October 8, 2019. 02/19 Paracrine hormone hypothesis of colorectal cancer. What every doctor should know: A general medical update. Vail, CO, February 3-6, 2019. 09/18 Paracrine hormone hypothesis of colorectal cancer. Itom International Conference on the Biology, Chemistry and Therapeutic Applications of Nitric Oxide, Oxford, UK, September 16-20, 2018. 07/18 Paracrine hormone hypothesis of colorectal cancer. Ironwood Pharmaceuticals, Inc., Cambridge, MA, July 14, 2018. 05/18 Paracrine hormone hypothesis of colorectal cancer. Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018. 03/18 Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018. 2/18 Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting, 	1977	Student Instructor, Neuroanatomy, (Professor Norman Moskowitz),
 1976 Student Instructor, Histology (Professor August Epple), Daniel Baugh Institute of Anatomy. Stanford University 1990 Instructor, Introduction To Clinical Medicine And Physical Diagnosis (Christopher Snow, M.D.), Department of Medicine. 1990 Lecturer, Endocrine Physiology (Professor Andrew Hoffman), Department of Physiology. PRESENTATIONS 09/22 Clinical trials of GUCY2C (GCC) agonists for colorectal cancer prevention. Translational Advances in Cancer Prevention Agent Development (TACPAD). NCI. September 7-9, 2022. 10/19 Translating GUCY2C as a target for colorectal cancer chemoprevention. Bench to Bedside and Beyond: Translational Research to Real World Evidence. Janssen, Titusville, NJ, October 8, 2019. 02/19 Paracrine hormone hypothesis of colorectal cancer. What every doctor should know: A general medical update. Vail, CO, February 3-6, 2019. 09/18 Paracrine hormone hypothesis of colorectal cancer. 10th International Conference on the Biology, Chemistry and Therapeutic Applications of Nitric Oxide, Oxford, UK, September 16-20, 2018. 07/18 Paracrine hormone hypothesis of colorectal cancer. Ironwood Pharmaceuticals, Inc., Cambridge, MA, July 14, 2018. 05/18 Paracrine hormone hypothesis of colorectal cancer. Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018. 03/18 Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018. 2/18 Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting, 	1977	Prosector and Student Instructor, Gross Anatomy (Professor Jay Shea),
Stanford University1990Instructor, Introduction To Clinical Medicine And Physical Diagnosis (Christopher Snow, M.D.), Department of Medicine.1990Lecturer, Endocrine Physiology (Professor Andrew Hoffman), Department of Physiology.PRESENTATIONS09/22Clinical trials of GUCY2C (GCC) agonists for colorectal cancer prevention. Translational Advances in Cancer Prevention Agent Development (TACPAD). NCI. September 7-9, 2022.10/19Translating GUCY2C as a target for colorectal cancer chemoprevention. Bench to Bedside and Beyond: Translational Research to Real World Evidence. Janssen, Titusville, NJ, October 8, 2019.02/19Paracrine hormone hypothesis of colorectal cancer. What every doctor should know: A general medical update. Vail, CO, February 3-6, 2019.09/18Paracrine hormone hypothesis of colorectal cancer. 10th International Conference on the Biology, Chemistry and Therapeutic Applications of Nitric Oxide, Oxford, UK, September 16-20, 2018.07/18Paracrine hormone hypothesis of colorectal cancer. Ironwood Pharmaceology, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018.03/18Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018.2/18Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting,	1976	Student Instructor, Histology (Professor August Epple), Daniel Baugh
 1990 Instructor, Introduction To Clinical Medicine And Physical Diagnosis (Christopher Snow, M.D.), Department of Medicine. 1990 Lecturer, Endocrine Physiology (Professor Andrew Hoffman), Department of Physiology. PRESENTATIONS 09/22 Clinical trials of GUCY2C (GCC) agonists for colorectal cancer prevention. Translational Advances in Cancer Prevention Agent Development (TACPAD). NCI. September 7-9, 2022. 10/19 Translating GUCY2C as a target for colorectal cancer chemoprevention. Bench to Bedside and Beyond: Translational Research to Real World Evidence. Janssen, Titusville, NJ, October 8, 2019. 02/19 Paracrine hormone hypothesis of colorectal cancer. What every doctor should know: A general medical update. Vail, CO, February 3-6, 2019. 09/18 Paracrine hormone hypothesis of colorectal cancer. 10th International Conference on the Biology, Chemistry and Therapeutic Applications of Nitric Oxide, Oxford, UK, September 16-20, 2018. 07/18 Paracrine hormone hypothesis of colorectal cancer. Ironwood Pharmaceuticals, Inc., Cambridge, MA, July 14, 2018. 05/18 Paracrine hormone hypothesis of colorectal cancer. Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018. 03/18 Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018. 2/18 Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting, 	Stanford Universi	-
of Physiology.PRESENTATIONS09/22Clinical trials of GUCY2C (GCC) agonists for colorectal cancer prevention. Translational Advances in Cancer Prevention Agent Development (TACPAD). NCI. September 7-9, 2022.10/19Translating GUCY2C as a target for colorectal cancer chemoprevention. Bench to Bedside and Beyond: Translational Research to Real World Evidence. Janssen, Titusville, NJ, October 8, 2019.02/19Paracrine hormone hypothesis of colorectal cancer. What every doctor should know: A general medical update. Vail, CO, February 3-6, 2019.09/18Paracrine hormone hypothesis of colorectal cancer. 10th International Conference on the Biology, Chemistry and Therapeutic Applications of Nitric Oxide, Oxford, UK, September 16-20, 2018.07/18Paracrine hormone hypothesis of colorectal cancer. Ironwood Pharmaceuticals, Inc., Cambridge, MA, July 14, 2018.05/18Paracrine hormone hypothesis of colorectal cancer. Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018.03/18Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018.2/18Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting,		Instructor, Introduction To Clinical Medicine And Physical Diagnosis
 O9/22 Clinical trials of GUCY2C (GCC) agonists for colorectal cancer prevention. Translational Advances in Cancer Prevention Agent Development (TACPAD). NCI. September 7-9, 2022. Translating GUCY2C as a target for colorectal cancer chemoprevention. Bench to Bedside and Beyond: Translational Research to Real World Evidence. Janssen, Titusville, NJ, October 8, 2019. Paracrine hormone hypothesis of colorectal cancer. What every doctor should know: A general medical update. Vail, CO, February 3-6, 2019. Paracrine hormone hypothesis of colorectal cancer. 10th International Conference on the Biology, Chemistry and Therapeutic Applications of Nitric Oxide, Oxford, UK, September 16-20, 2018. Paracrine hormone hypothesis of colorectal cancer. Ironwood Pharmaceuticals, Inc., Cambridge, MA, July 14, 2018. Paracrine hormone hypothesis of colorectal cancer. Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018. Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018. Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting, 	1990	
 O9/22 Clinical trials of GUCY2C (GCC) agonists for colorectal cancer prevention. Translational Advances in Cancer Prevention Agent Development (TACPAD). NCI. September 7-9, 2022. Translating GUCY2C as a target for colorectal cancer chemoprevention. Bench to Bedside and Beyond: Translational Research to Real World Evidence. Janssen, Titusville, NJ, October 8, 2019. Paracrine hormone hypothesis of colorectal cancer. What every doctor should know: A general medical update. Vail, CO, February 3-6, 2019. Paracrine hormone hypothesis of colorectal cancer. 10th International Conference on the Biology, Chemistry and Therapeutic Applications of Nitric Oxide, Oxford, UK, September 16-20, 2018. Paracrine hormone hypothesis of colorectal cancer. Ironwood Pharmaceuticals, Inc., Cambridge, MA, July 14, 2018. Paracrine hormone hypothesis of colorectal cancer. Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018. Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018. Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting, 	PRESENTATIONS	
Translational Advances in Cancer Prevention Agent Development (TACPAD). NCI. September 7-9, 2022.10/19Translating GUCY2C as a target for colorectal cancer chemoprevention. Bench to Bedside and Beyond: Translational Research to Real World Evidence. Janssen, Titusville, NJ, October 8, 2019.02/19Paracrine hormone hypothesis of colorectal cancer. What every doctor should know: A general medical update. Vail, CO, February 3-6, 2019.09/18Paracrine hormone hypothesis of colorectal cancer. 10th International Conference on the Biology, Chemistry and Therapeutic Applications of Nitric Oxide, Oxford, UK, September 16-20, 2018.07/18Paracrine hormone hypothesis of colorectal cancer. Intric Oxide, Oxford, UK, September 16-20, 2018.05/18Paracrine hormone hypothesis of colorectal cancer. Division of Clinical Pharmaceuticals, Inc., Cambridge, MA, July 14, 2018.05/18Paracrine hormone hypothesis of colorectal cancer. Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018.03/18Paracrine hormone hypothesis of colorectal cancer. Division of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018.2/18Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting,		Clinical trials of GUCY2C (GCC) agonists for colorectal cancer prevention.
 10/19 Translating GUCY2C as a target for colorectal cancer chemoprevention. Bench to Bedside and Beyond: Translational Research to Real World Evidence. Janssen, Titusville, NJ, October 8, 2019. 02/19 Paracrine hormone hypothesis of colorectal cancer. What every doctor should know: A general medical update. Vail, CO, February 3-6, 2019. 09/18 Paracrine hormone hypothesis of colorectal cancer. 10th International Conference on the Biology, Chemistry and Therapeutic Applications of Nitric Oxide, Oxford, UK, September 16-20, 2018. 07/18 Paracrine hormone hypothesis of colorectal cancer. Ironwood Pharmaceuticals, Inc., Cambridge, MA, July 14, 2018. 05/18 Paracrine hormone hypothesis of colorectal cancer. Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018. 03/18 Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018. 2/18 Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting, 		
 Bench to Bedside and Beyond: Translational Research to Real World Evidence. Janssen, Titusville, NJ, October 8, 2019. 02/19 Paracrine hormone hypothesis of colorectal cancer. What every doctor should know: A general medical update. Vail, CO, February 3-6, 2019. 09/18 Paracrine hormone hypothesis of colorectal cancer. 10th International Conference on the Biology, Chemistry and Therapeutic Applications of Nitric Oxide, Oxford, UK, September 16-20, 2018. 07/18 Paracrine hormone hypothesis of colorectal cancer. Ironwood Pharmaceuticals, Inc., Cambridge, MA, July 14, 2018. 05/18 Paracrine hormone hypothesis of colorectal cancer. Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018. 03/18 Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018. 2/18 Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting, 		(TACPAD). NCI. September 7-9, 2022.
 Evidence. Janssen, Titusville, NJ, October 8, 2019. 02/19 Paracrine hormone hypothesis of colorectal cancer. What every doctor should know: A general medical update. Vail, CO, February 3-6, 2019. 09/18 Paracrine hormone hypothesis of colorectal cancer. 10th International Conference on the Biology, Chemistry and Therapeutic Applications of Nitric Oxide, Oxford, UK, September 16-20, 2018. 07/18 Paracrine hormone hypothesis of colorectal cancer. Ironwood Pharmaceuticals, Inc., Cambridge, MA, July 14, 2018. 05/18 Paracrine hormone hypothesis of colorectal cancer. Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018. 03/18 Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018. 2/18 Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting, 	10/19	Translating GUCY2C as a target for colorectal cancer chemoprevention.
 02/19 Paracrine hormone hypothesis of colorectal cancer. What every doctor should know: A general medical update. Vail, CO, February 3-6, 2019. 09/18 Paracrine hormone hypothesis of colorectal cancer. 10th International Conference on the Biology, Chemistry and Therapeutic Applications of Nitric Oxide, Oxford, UK, September 16-20, 2018. 07/18 Paracrine hormone hypothesis of colorectal cancer. Ironwood Pharmaceuticals, Inc., Cambridge, MA, July 14, 2018. 05/18 Paracrine hormone hypothesis of colorectal cancer. Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018. 03/18 Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018. 2/18 Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting, 		•
 should know: A general medical update. Vail, CO, February 3-6, 2019. <i>Paracrine hormone hypothesis of colorectal cancer.</i> 10th International Conference on the Biology, Chemistry and Therapeutic Applications of Nitric Oxide, Oxford, UK, September 16-20, 2018. <i>Paracrine hormone hypothesis of colorectal cancer.</i> Ironwood Pharmaceuticals, Inc., Cambridge, MA, July 14, 2018. <i>Paracrine hormone hypothesis of colorectal cancer.</i> Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018. <i>Paracrine hormone hypothesis of colorectal cancer.</i> 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018. <i>Differentiating Therapies For CIC and IBS-C.</i> Synergy Advisory Meeting, 		
 09/18 Paracrine hormone hypothesis of colorectal cancer. 10th International Conference on the Biology, Chemistry and Therapeutic Applications of Nitric Oxide, Oxford, UK, September 16-20, 2018. 07/18 Paracrine hormone hypothesis of colorectal cancer. Ironwood Pharmaceuticals, Inc., Cambridge, MA, July 14, 2018. 05/18 Paracrine hormone hypothesis of colorectal cancer. Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018. 03/18 Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018. 2/18 Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting, 	02/19	
 Conference on the Biology, Chemistry and Therapeutic Applications of Nitric Oxide, Oxford, UK, September 16-20, 2018. 07/18 Paracrine hormone hypothesis of colorectal cancer. Ironwood Pharmaceuticals, Inc., Cambridge, MA, July 14, 2018. 05/18 Paracrine hormone hypothesis of colorectal cancer. Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018. 03/18 Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018. 2/18 Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting, 	00/10	•
 Nitric Oxide, Oxford, UK, September 16-20, 2018. 07/18 Paracrine hormone hypothesis of colorectal cancer. Ironwood Pharmaceuticals, Inc., Cambridge, MA, July 14, 2018. 05/18 Paracrine hormone hypothesis of colorectal cancer. Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018. 03/18 Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018. 2/18 Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting, 	09/18	
 07/18 Paracrine hormone hypothesis of colorectal cancer. Ironwood Pharmaceuticals, Inc., Cambridge, MA, July 14, 2018. 05/18 Paracrine hormone hypothesis of colorectal cancer. Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018. 03/18 Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018. 2/18 Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting, 		
 Pharmaceuticals, Inc., Cambridge, MA, July 14, 2018. Paracrine hormone hypothesis of colorectal cancer. Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018. Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018. Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting, 	07/18	
 05/18 Paracrine hormone hypothesis of colorectal cancer. Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018. 03/18 Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018. 2/18 Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting, 	07/10	
 Pharmacology, Departments of Medicine and Pharmacology, Johns Hopkins University, Baltimore, MD, May 23, 2018. 03/18 <i>Paracrine hormone hypothesis of colorectal cancer.</i> 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018. 2/18 <i>Differentiating Therapies For CIC and IBS-C.</i> Synergy Advisory Meeting, 	05/18	
 Hopkins University, Baltimore, MD, May 23, 2018. 03/18 Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018. 2/18 Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting, 	00, 20	
 03/18 Paracrine hormone hypothesis of colorectal cancer. 2018 Marcus M. Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical College, New York, March 13, 2018. 2/18 Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting, 		
College, New York, March 13, 2018. 2/18 Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting,	03/18	
2/18 Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting,		Reidenberg Lecture, Department of Pharmacology, Weill-Cornell Medical
		College, New York, March 13, 2018.
Dallas TV Echryany 22 24 2019	2/18	Differentiating Therapies For CIC and IBS-C. Synergy Advisory Meeting,
•		Dallas, TX, February 23-24, 2018.
1/18 <i>PharmGKB Future Directions</i> , Expert Panel, NHGRI PharmGKB Future	1/18	•
Directions, Bethesda, MD, January 23, 2018.		
1/18 GUCY2C ligands to treat visceral nain Key Oninion Leaders Meeting	1/18	GUCY2C ligands to treat visceral pain. Key Opinion Leaders Meeting,
	1/10	
Synergy Pharmaceuticals, New York, New York, January 19-20, 2018.	1/10	Department of Anatomy, Cell Biology, and Pathology, Thomas Jefferson University, Philadelphia, PA, January 19, 2018.
Synergy Pharmaceuticals, New York, New York, January 19-20, 2018.	1/18	Hormone suppression silencing GUCY2C is required for colorectal cancer.
Synergy Pharmaceuticals, New York, New York, January 19-20, 2018.1/18Hormone suppression silencing GUCY2C is required for colorectal cancer.		

Раде Д

12/17	<i>Hormone suppression silencing GUCY2C is required for colorectal cancer.</i> Visiting Professor, GI Core Center, Division of Gastroenterology & Hepatology, Department of Medicine, Johns Hopkins University,
	Baltimore, MD, December 19, 2017.
11/17	<i>Paracrine hormone hypothesis of colorectal cancer</i> . Visiting Professor, Department of Microbiology and Immunology, Drexel University, Philadelphia, PA, November 29, 2017.
10/17	<i>GUCY2C ligands to treat chronic constipation syndromes.</i> Synergy Satellite Meeting, American College of Gastroenterology National Meeting, Orlando, FL, October 17, 2017.
07/17	<i>GUCY2C ligands to treat visceral pain.</i> Synergy Satellite Meeting, American Neurogastroenterology and Motility Society, New York, New York, August 3, 2017.
06/17	<i>GUCY2C ligands to treat visceral pain.</i> Synergy Advisory Meeting, Washington, D.C., June 16-17, 2017.
06/17	<i>Guanylate cyclase at the intersection of colorectal cancer and obesity.</i> 8th International Conference on cGMP. cGMP: Generators, Effectors, and Therapeutic Implications, June 22-225, Bamburg, Germany.
05/17	<i>Translational Medicine: From Knowledge Generation To Healthcare</i> <i>Delivery.</i> Grand Rounds, Abington Health System, Philadelphia, PA, May 24, 2017.
05/17	<i>Translational Medicine: From Knowledge Generation To Healthcare</i> <i>Delivery.</i> Grand Rounds, Xuzhou Medical University, Xuzhou, China, May 24, 2017.
05/17	Translational Medicine: From Knowledge Generation To Healthcare
03/17	Delivery. Grand Rounds, Wuxi Second People's Hospital, Wuxi, China, May 19, 2017.
05/17	<i>Paracrine hormone hypothesis of colorectal cancer</i> . Visiting Professor, Department of Cell Biology and Pharmacology, Florida International University, Miami, Florida, May 2-3, 2017.
04/17	<i>Advancing immune-oncology for gastrointestinal cancers</i> . ICV Philadelphia: Healthcare Innovation Forum, Philadelphia, PA, April 25, 2017.
03/17	<i>Paracrine hormone hypothesis of colorectal cancer</i> . Visiting Professor, Department of Biomedical Engineering, University of Delaware, Newark, DE, March 27, 2017.
02/17	GUCY2C ligands to treat chronic constipation syndromes. Synergy Advisory Meeting, Orlando, FL, February 18, 2017.
02/17	<i>Advancing immune-oncology for gastrointestinal cancers.</i> What every doctor should know: A general medical update. British Columbia, February 5-10, 2017.
01/17	<i>Paracrine hormone hypothesis of colorectal cancer.</i> American Medical School Pharmacology Chairs, Oaxaca, Mexico, January 25-29, 2017.
01/17	Colorectal cancer prevention by GUCY2C signaling. Fox Chase Cancer Center, Philadelphia, PA, January 24, 2017.

Dage 5

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.